Skip to main content

Singulex Collaborating with Novartis, Opening European Facility

NEW YORK (GenomeWeb News) – Alameda, Calif.-based Singulex announced yesterday that it is collaborating with the Swiss pharmaceutical company Novartis and that it has opened a new facility in Paris to serve European collaborators.
Under the agreement, a Novartis facility in Basel, Switzerland, has acquired Singulex’s Erenna system, which is used for detecting changes in protein biomarkers in samples from several species. In addition, Singulex plans to help Novartis create biomarker assays related to the pharmaceutical company’s drug development programs.
Terms of the collaboration were not disclosed.
Meanwhile, the Singulex center in France is intended to bring Singulex’s biomarker diagnostic systems and immunoassay technology, including Erenna, closer to its European partners.

The Scan

Gap in COVAX Doses

BBC News reports that COVAX is experiencing a vaccine shortfall, as the Serum Institute of India has paused exports.

Sanofi, GSK Report Promising Results

The Wall Street Journal reports that the candidate SARS-CoV-2 vaccine from Sanofi and GlaxoSmithKline has had encouraging early results.

Influence of Luck

The New York Times examines how the US avoided variant-fueled increases in COVID-19 cases.

PLOS Papers on Retina GWAS, Hantaan Virus, COVID-19 Phenome-Wide Association Study

In PLOS this week: genome-wide association study of retinal morphology, analysis of hantaan virus found in a mouse, and more.